Formulation And In Vivo Evaluation Of Sonidegib Loaded Poly Ethyl Methacrylate Nanoparticles For Effective Treatment Of Cancer

Abstract

The present research is aimed to develop and evaluate sonidegib loaded poly (ethyl methacrylate) nanoparticles (PEM-NPs) to improve its resistance towards pH and chemical conditions in exposed cancerous lesions. 17 formulations of sonidegib loaded PEM-NPs prepared using 3-factor Box–Behnken design analyzed at 3-levels. Three batches of sonidegib loaded PEM-NPs F1, F2, F3 were prepared based on predicted dependent variables and characterized for least particle size and maximum percentage conversion. The in vitro release study indicated an improvement in drug release of formulation F3 (95.878 %) than pure drug (2.86%). In vivo pharmacokinetic studies were conducted for optimized sonidegib PEM nanoparticles on rats, indicates that C_max of the nanoparticles (98.43±4.21ng/ml)was significant (p<0.05), T_max of both nanoparticle formulation and pure drug suspension was 4.00±0.03 and 6.00±0.01h, respectively. AUC_0-∞ for nanoparticles formulation was higher (519.1±5.14ng.h/ml) than the pure drug suspension formulation (93.7±6.22 ng.h/ml), the bioavailability was more than 5 folds increased. These results marked that the proposed SLNs were effective in improving the bioavailability of sonidegib.